<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03996616</url>
  </required_header>
  <id_info>
    <org_study_id>GRAVITY</org_study_id>
    <nct_id>NCT03996616</nct_id>
  </id_info>
  <brief_title>Head-up Position and High Quality Cardiopulmonary Resuscitation in OHCA</brief_title>
  <acronym>GRAVITY</acronym>
  <official_title>Head-up Position, Active Compression-decompression Mechanical Cardiopulmonary Resuscitation and Impedance Threshold Device to Improve Outcomes in Out-of-hospital Cardiac Arrest. A Multicenter Prospective Controlled Quasi-experimental Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Elevation of the head and thorax, also known as Head-up cardiopulmonary resuscitation (HUP
      CPR), has been studied extensively in pigs in ventricular fibrillation (VF). HUP combined
      with active compression decompression and impedance threshold device (ACD+ITD) CPR improves
      vital organ perfusion and results in a doubling of cerebral perfusion when compared with the
      same method of CPR in the flat or horizontal plane. HUP CPR enhances the drainage of venous
      blood from the brain, lowers central venous pressures, reduces intracranial pressures during
      the decompression phase of CPR, redistributes blood flow through the lungs during CPR, and
      may reduce brain edema. These mechanisms collectively contribute to improved blood flow and
      less injury to the brain during CPR. These benefits are due in large part to the effects of
      gravity on the physiology of HUP CPR. Importantly, HUP CPR is dependent upon a means of
      generating enough forward flow to adequately pump blood &quot;uphill&quot; to the brain.

      In this proposed pilot study, CPR will be performed manually before the patient is placed on
      a controlled mechanical elevation device (Elegard, Minnesota Resuscitation Solutions LLC,
      USA). An ITD-16 (ResQPOD-16, Zoll, USA) will be placed on the patient's airway before the
      head is elevated. Automated CPR will be initiated as soon as feasible using a new automated
      CPR mechanical compression device that provides full active compression-decompression CPR
      (LUCAS-AD, Stryker, USA).

      The proposed feasibility clinical study will be the first ever to test the fully integrated
      system of ACD+ITD HUP CPR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elevation of the head and thorax, also known as Head-up cardiopulmonary resuscitation (HUP
      CPR), has been studied extensively in pigs in ventricular fibrillation (VF). HUP combined
      with active compression decompression and impedance threshold device (ACD+ITD) CPR improves
      vital organ perfusion and results in a doubling of cerebral perfusion when compared with the
      same method of CPR in the flat or horizontal plane. HUP CPR enhances the drainage of venous
      blood from the brain, lowers central venous pressures, reduces intracranial pressures during
      the decompression phase of CPR, redistributes blood flow through the lungs during CPR, and
      may reduce brain edema. These mechanisms collectively contribute to improved blood flow and
      less injury to the brain during CPR. These benefits are due in large part to the effects of
      gravity on the physiology of HUP CPR. Importantly, HUP CPR is dependent upon a means of
      generating enough forward flow to adequately pump blood &quot;uphill&quot; to the brain.

      Animal studies have shown that HUP CPR must be performed in a specific manner to be
      effective. For example, conventional standard CPR is insufficient, by itself, for effective
      HUP CPR. Additional means to enhance circulation are needed, such as concurrent use of the
      ITD and ACD CPR devices. ACD+ITD CPR alone has been shown to improve hemodynamics and
      survival with favorable neurologic outcome in several human randomized control trials. Animal
      studies have shown that HUP CPR is best with the combination of ACD+ITD CPR. Studies have
      shown that CPR must be initiated before elevating the head. Studies have also shown that HUP
      CPR is dependent upon the time it takes to elevate the head to the HUP. Elevation of the head
      and thorax should optimally take place over a 2-minute period of time from a flat position to
      the maximum head up elevation level in order to optimize cerebral perfusion pressures. Too
      rapid an elevation of the head and thorax can result in a reduction in cerebral arterial
      pressure when compared with flat CPR.

      In this proposed pilot study, CPR will be performed manually before the patient is placed on
      a controlled mechanical elevation device (Elegard, Minnesota Resuscitation Solutions LLC,
      USA). An ITD-16 (ResQPOD-16, Zoll, USA) will be placed on the patient's airway before the
      head is elevated. Automated CPR will be initiated as soon as feasible using a new automated
      CPR mechanical compression device that provides full active compression-decompression CPR
      (LUCAS-AD, Stryker, USA).

      The proposed feasibility clinical study will be the first ever to test the fully integrated
      system of ACD+ITD HUP CPR.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Prospective, quasi-experimental, controlled, pre- and post-intervention trial, using a difference-in-differences design and involving two study sites</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>End-tidal carbon dioxide (ETCO2)</measure>
    <time_frame>Day 0</time_frame>
    <description>The maximum value of ETCO2 during CPR before ROSC measured after a washout period of 4 positive pressure ventilations (~30 seconds with 30:2 compression: ventilation ratio) will be recorded. ETCO2 value reflects both cardiac output (CO) and pulmonary blood flow, and is an indirect indicator of coronary perfusion pressure during CPR. Levels of ETCO2 &gt; 10-15 mmHg have been correlated with return of spontaneous circulation (ROSC) and survival in both animal and human models of cardiac arrest.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Return of spontaneous circulation (ROSC)</measure>
    <time_frame>Day 0</time_frame>
    <description>Proportion of patients who's recovered a spontaneous circulation after CPR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alive at hospital admission</measure>
    <time_frame>Day 0</time_frame>
    <description>Vital status at hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival to hospital discharge</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Vital status at hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Vital status at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological functional status</measure>
    <time_frame>Day 30</time_frame>
    <description>As measured by using the modified Rankin Scale (a mRS score less or equal to 3 will be considered as favourable neurologic outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First recorded rhythm</measure>
    <time_frame>Day 0</time_frame>
    <description>First recorded rhythm and rhythm recorded by EMS (asystole, ryhtme without pulse, ventricular fibrillation or ventricular tacycardia and spontaneous circulation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in heart rhythm from ventricular fibrillation (VF)</measure>
    <time_frame>Day 0</time_frame>
    <description>Proportion of patients who's with changes in heart rhythm from VF to non-VF rhythm and vice versa during the EMS intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Signs of life</measure>
    <time_frame>Day 0</time_frame>
    <description>Presence of agonal respirations and other signs of life (pupillary response, movement during CPR) recorded by ALS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-arrest rates</measure>
    <time_frame>Day 0</time_frame>
    <description>We calculated the proportion of patients who's recovered another cardiac arrest during CPR (supported by ALS and EMS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-invasive arterial O2</measure>
    <time_frame>Day 0</time_frame>
    <description>Non-invasive arterial O2 saturation values during CPR recorded by EMS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-tidal carbon dioxide (ETCO2)</measure>
    <time_frame>Day 0</time_frame>
    <description>We compared the difference in ETCO2 values between baseline (i.e., within 2 minutes of CPR initiation) and repeated (i.e., within 4 minutes of CPR initiation) measures during the CPR (recorded by ALS and EMS intervention)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-invasive cerebral oximetry (rsO2)</measure>
    <time_frame>Day 0</time_frame>
    <description>Non-invasive cerebral oximetry (rsO2) values during CPR repeated (i.e., within 4 minutes of CPR initiation) measures recorded by ALS and EMS intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular (LV) function</measure>
    <time_frame>Day 0</time_frame>
    <description>LV function will be measured by echocardiography within 12 hours of ROSC at hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-invasive measurement of blood pressure</measure>
    <time_frame>Day 0</time_frame>
    <description>Non-invasive measurement of blood (systolic, diastolic and mean blood pressure) pressure during CPR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intubation difficulty</measure>
    <time_frame>Day 0</time_frame>
    <description>Intubation difficulty assessed by the Intubation Difficulty Scale score. Score equal at 0 will be considered to easy intubation, score between 0 and 5 will be considered to slight difficulty, score more than 5 will be considered to moderate to major difficulty and score equal to infinite will be considered to impossible intubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuron specific enolase</measure>
    <time_frame>Day 0 and 24hours</time_frame>
    <description>Serum Neuron specific enolase was measured at admission and 24h after hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S100 protein</measure>
    <time_frame>Day 0 and 24hours</time_frame>
    <description>Serum S100 protein was measured- at admission and 24h after hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Blood gases</measure>
    <time_frame>Day 0</time_frame>
    <description>Arterial blood gases (PaO2 partial pressure of oxygen, PCO2 partial pressure of cardon dioxide, pH, HCO3- bicarbonates and SaO2 oxygen saturation) were measured at hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lactate</measure>
    <time_frame>Day 0</time_frame>
    <description>Serum lactate was measured at hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum d-dimer</measure>
    <time_frame>Day 0 and 24hours</time_frame>
    <description>Serum d-dimer was measured at 4hour and 24 hour after admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin C</measure>
    <time_frame>Day 0 and 24hours</time_frame>
    <description>Troponin C was measured at 4hour and 24 hour after admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>Day 0 and 24hours</time_frame>
    <description>creatinine, ASAT and ALAT were measured at 4hour and 24 hour after admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transaminases</measure>
    <time_frame>Day 0 and 24hours</time_frame>
    <description>The transaminases (ASAT: aspartate aminotransferases and ALAT: alanine aminotransferases) were measured at 4hour and 24 hour after admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging</measure>
    <time_frame>12 hours</time_frame>
    <description>Head CT will be performed within 12 hours of ROSC. Analysis will include the white to gray matter ratio</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">194</enrollment>
  <condition>Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>During the pre-intervention period, patients will receive standard CPR in the two study groups. Standard CPR will be performed according to the current guidelines.
The only changes in current practice for the control will be the monitoring of EtCO2 and cerebral oxymetry as early as possible for the firefighter. ETCO2 will be recorded using a small portable ETCO2 monitor (EMMA, Masimo, USA). EMS first responders will receive a specific training in both group to use, recording, and reporting of ETCO2 value during CPR. This device has CE mark (see related CE mark and user manual). Cerebral oximetry will be recorded using a new small portable device (HR500, Nonin, USA). This device allows using an easy to use adhesive sensor with remote Bluetooth connection to a smartphone sized monitor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Assigned Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the post-intervention period, patients assigned in the intervention group will receive the evaluated intervention (i.e., HUP and ACD-ITD CPR HUP using the 3 devices in combinations, Elegard, Lucas AD and ITD-16)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Assigned Intervention</intervention_name>
    <description>Patients will be treated with manual standard CPR ASAP upon arrival of EMS first responders, transferred to Elegard device as soon as possible, and then treated with HUP and ACD+ITD CPR using the LUCAS AD and ResQPOD-16.
Rescuers will perform CPR as continuously as possible during the placement of the Elegard, with a &lt;10 second pause in chest compressions during the placement of this device. This is similar to the manner in which the LUCAS compressor and back plate are placed at the present time. After performing LUCAS AD + ITD CPR for 2 minutes with the head in the 'flat' position, the Elegard device will be turned on and the head will begin to rise as long as the patient is being treated with the ResQPOD-16 and the LUCAS AD. The head will be elevated to approximately 22 cm from the ground to the back of the occiput.</description>
    <arm_group_label>Assigned Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years old on enrollment

          -  Witnessed out-of-hospital cardiac arrest

        Exclusion Criteria:

          -  Obvious pregnancy at inclusion

          -  Cardiac arrest of traumatic origin (including drowning or hanging)

          -  Cardiac arrest for which resuscitation seems unjustified (inevitable death, terminally
             ill irreversible condition, too long duration of cardiac arrest, advance personal
             directives of no-resuscitation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monique Sorentino</last_name>
    <role>Study Director</role>
    <affiliation>CHU Grenoble Alpes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume DEBATY, MD</last_name>
    <phone>0033476634202</phone>
    <email>gdebaty@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline Sanchez, PhD</last_name>
    <phone>0033476634256</phone>
    <email>csanchez5@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>SAMU 38</name>
      <address>
        <city>Grenoble</city>
        <state>Is√®re</state>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Guillaume Debaty, Md, PhD</last_name>
      <email>gdebaty@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SAMU 54 - CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <state>Meurthe-et-Moselle</state>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Chouihed Tahar, MD, PhD</last_name>
      <email>t.chouihed@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <last_update_submitted>June 20, 2019</last_update_submitted>
  <last_update_submitted_qc>June 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac Arrest</keyword>
  <keyword>Cardiopulmonary Resuscitation</keyword>
  <keyword>Head-up position</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study protocol will be submitted for publication. IPD will be shared with other researcher</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available within 6 months of study completion</ipd_time_frame>
    <ipd_access_criteria>Data will be available with no restriction</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

